BioInvenu Corporation provides proprietary cell-based assay products and services to drug discovery researchers utilizing a novel cell-based protein-protein interaction assay technology, LinkLight™ technology. Special pricing is offered to academic customers.
LinkLight™ technology has been applied to G-protein coupled receptors (GPCR), nuclear hormone receptors (NHR), and receptor tyrosine kinases (RTK) by utilizing receptor and its signal adaptor interaction as the functional signal readout. Biologically relevant compounds that modulate protein-protein interactions can be identified with this highly sensitive, specific, and robust assay method. Very recently, cell-based non-receptor kinase and signal adaptor protein interaction LinkLight™ assays have been established. The technology has the potential for a broad range of drug targets that are difficult to tackle by existing methods.
Cellular signal transduction depends on protein-protein interactions. Protein-protein interactions are dynamically regulated by reversible post-translational modifications (PTM) such as phosphorylation and dephosphorylation. Phosphorylation can induce protein conformational changes, and enable phosphorylated proteins to interact with other proteins, change protein subcellular locations, and transduce signals through phosphorylation-mediated protein-protein interaction networks. Using protein-protein interactions as functional signal readouts to decipher functions of poorly characterized proteins opens opportunities of both mechanism illustration of their signaling pathways and practical relevance of developing HTS methods.
BioInvenu has the exclusive license for LinkLight™ technology and is dedicated to expanding cell lines offered as well as providing services around novel protein-protein interaction assays.
We specialize in measuring protein-protein interaction in a cellular context using LinkLight™ technology. Please contact us with your specific request.
We will develop custom cell-based protein-protein interaction assays based on LinkLight™ technology for customers.
BioInvenu provides a wide range of services to facilitate your research including customer assay development, compound profiling, cell line generation, and bulk transient expression in cells.
All of the IP generated by our services is owned by our clients.
BioInvenu offers custom assay development services to meet your individual needs. All projects are carried out in close consultation with the respective project partners. Special consideration given to academic researchers.
We will help with experimental design as needed for our cell-based assay and compound profiling services.
BioInvenu provides custom cell line generation services to meet your specific needs in high throughput screening.
Stable Cell lines
Frozen Transient Expression Cells
BioInvenu offers compound profiling service. BioInvenu has a panel of human GPCR ß-arrestin assays. Customers can choose from a wide range human GPCR targets for assessing compound activity and specificity. BioInvenu NHR panel and RTK panel will be soon available for compound profiling services.
Flexible by Design: In additional to LinkLight™ assays, BioInvenu can provide cAMP assays for biased ligand evaluation for GPCRs.
Rapid Data Turnaround: 1-2 weeks from receiving compound to delivering dataset and additional two weeks for delivering formal report.
Predicting compound liver toxicity by using a PXR/CYP3A4 luciferase reporter HepG2 cell assay
Services for GPCR/β-arrestin signaling pathway assays, GPCR/14-3-3 signaling pathway assays, cell-based kinase assays based on kinase and its signal adaptor interactions, and PXR/CYP3A4 luciferase reporter assay.
We will help you analyze pharmacological consequences of your protein-protein interaction measurements using LinkLight™ technology.
Lead Identification and Validation Services
BioInvenu has not received any reviews.
BioInvenu has not received any endorsements.